Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

43.14
+0.55001.29%
Post-market: 43.140.00000.00%19:43 EDT
Volume:2.96M
Turnover:127.15M
Market Cap:103.36B
PE:23.14
High:43.23
Open:42.82
Low:42.82
Close:42.59
52wk High:52.68
52wk Low:40.89
Shares:2.40B
Float Shares:2.16B
Volume Ratio:1.26
T/O Rate:0.14%
Dividend:2.37
Dividend Rate:5.49%
EPS(TTM):1.86
EPS(LYR):3.76
ROE:5.71%
ROA:5.09%
PB:1.30
PE(LYR):11.48

Loading ...

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

GlobeNewswire
·
Apr 13

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

Dow Jones
·
Apr 10

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

Dow Jones
·
Apr 10

Sanofi becomes market authorization holder for Nuvaxovid in Canada

TIPRANKS
·
Apr 09

Sanofi Says Lunsekimig Meets Primary, Key Secondary Endpoints in Phase 2 Respiratory Studies

MT Newswires Live
·
Apr 07

Trump Will Impose 100% Tariff on Some Patented Drugs

Tiger Newspress
·
Apr 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Mar 31

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

Dow Jones
·
Mar 30

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires Live
·
Mar 27

Sanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support

MT Newswires Live
·
Mar 27

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

Dow Jones
·
Mar 27

Sanofi SA Stock (SNY) Moved Up by 3.33% on Mar 25: Key Drivers Unveiled

TradingKey
·
Mar 26

Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan

TIPRANKS
·
Mar 24

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

GlobeNewswire
·
Mar 24